Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

PURPOSE: Signaling pathway stimulation by activating mutations of oncogenes occurs in most melanomas and can provide excellent targets for therapy, but the short-term therapeutic success is limited by intrinsic and acquired resistance. The mitogen-activated protein kinase (MAPK) and PI3 kinase/AKT/m...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Margolin, Kim A., Moon, James, Flaherty, Lawrence E., Lao, Christopher D., Akerley, Wallace L., Othus, Megan, Sosman, Jeffrey A., Kirkwood, John M., Sondak, Vernon K.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3481165/
https://ncbi.nlm.nih.gov/pubmed/22228638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2488
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki